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Glioblastoma is the most common primary adult brain tumour, and despite optimal treatment, the median survival is 12–15
months. Patients with matched recurrent glioblastomas were investigated to try to find actionable mutations. Tumours were
profiled using a validated DNA-based gene panel. Copy number variations (CNVs) and single nucleotide variants (SNVs) were
examined, and potentially pathogenic variants and clinically actionable mutations were identified. 0e results revealed that
glioblastomas were IDH-wildtype (IDHWT; n� 38) and IDH-mutant (IDHMUT; n� 3). SNVs in TSC2,MSH6, TP53, CREBBP, and
IDH1 were variants of unknown significance (VUS) that were predicted to be pathogenic in both subtypes. IDHWT tumours had
SNVs that impacted RTK/Ras/PI(3)K, p53, WNT, SHH, NOTCH, Rb, and G-protein pathways. Many tumours had BRCA1/2
(18%) variants, including confirmed somatic mutations in haemangioblastoma. IDHWT recurrent tumours had fewer pathways
impacted (RTK/Ras/PI(3)K, p53, WNT, and G-protein) and CNV gains (BRCA2, GNAS, and EGFR) and losses (TERT and
SMARCA4). IDHMUT tumours had SNVs that impacted RTK/Ras/PI(3)K, p53, and WNT pathways. VUS in KLK1 was possibly
pathogenic in IDHMUT. Recurrent tumours also had fewer pathways (p53, WNT, and G-protein) impacted by genetic alterations.
Public datasets (TCGA and GDC) confirmed the clinical significance of findings in both subtypes. Overall in this cohort,
potentially actionable variation was most often identified in EGFR, PTEN, BRCA1/2, and ATM. 0is study underlines the need for
detailed molecular profiling to identify individual GBM patients who may be eligible for novel treatment approaches. 0is
information is also crucial for patient recruitment to clinical trials.
1. Introduction
Gliomas are the largest group of intrinsic brain tumours with
age adjusted incidence rates ranging from 4.67 to 5.73 per
100,000, causing more years of life lost compared with other
cancers [1, 2]. Glioblastoma (GBM) is the most malignant
glioma and is classified molecularly as IDH-wildtype and
IDH-mutant GBM [3–10]. During gliomagenesis, an array of
genetic alterations may cause the dysregulation of cell
growth signalling and cell cycle pathways [6, 11–15]. In
particular, mutations in RTKs (receptor tyrosine kinases)
and/or loss of PTEN (phosphatase and tensin homolog) alter
the PI3K (phospinositide 3-kinase)/AKT cell growth path-
way [11]. Further mutations in CDKN2A or CDK4 (cyclin-
dependent kinase) lead to uncontrolled progression of the
cell cycle, as do mutations in TP53 [16]. Neural stem cells in
the subventricular zone may harbour recurrent driver so-
matic mutations that are shared with the tumour bulk (e.g.,
P53, PTEN, EGFR, and TERT) [17]. Telomerase (reactivation
or reexpression) can occur in IDH wildtype and mutant
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GBMs driven either by telomerase reverse transcriptase
(TERT) promoter mutations or other mechanisms [8, 18].
0e current standard-of-care for glioblastomas remains as
maximal safe surgical resection with concurrent radio-
therapy and temozolomide (TMZ) chemotherapy (Stupp
protocol) [19, 20]. Personalised therapies remain promising
although trials have been unsuccessful to date [21–23]. For
example, dysregulated PI3K and RTKs (EGFR, MET,
PDGFR, FGFR, and BRAF) genes have been targeted with
various small molecules, antibodies, and inhibitors [24–29].
To date, entry to clinical trials for GBM has not been based
on a detailed molecular analysis of an individual patient’s
tumour using high throughput sequencing (HTS). HTS-
based molecular diagnostics can aid the detection of genetic
alterations, information required for personalised medicine
[30, 31]. Herein, initial and matched recurrent glioblastomas
were examined using HTS with a validated DNA-based
diagnostic panel. Potentially pathogenic variants and clin-
ically actionable mutations were identified in different GBM
subtypes. Findings were validated using TCGA-GBM and
GDC datasets.
2. Materials and Methods
2.1. Clinical Specimens. Ethical approval was given by Brain
Tumour Bank South West and Brain UK (Ref: 14/010). All
patients had been treated using the Stupp protocol [19]. A
total of 72 formalin-fixed paraffin-embedded (FFPE) sam-
ples from 54 patients were identified (2009–2014). Only
FFPE slides with >30% tumour cells available for macro-
dissection were selected. Samples lacking cellularity or ex-
cessively necrotic were excluded. Following quality control,
67 samples for 46 patients and 19 with matched recurrent
samples available were identified. Of these, a total of 49
samples were successfully sequenced for 41 patients (21males;
20 females; mean age 55 years, range 16–78 years; see Tables 1
and S1). Matched initial and recurrent tissue samples were
analysed for 8 patients (2 males; 6 females). Recurrent tu-
mours all occurred locally to the initial tumour. Anonymised
patient cases in the GBM cohort were numbered 1–11, 16–41,
and 43–46, and “a” and “b” indicated initial and recurrent
tumour samples, respectively (Table S1).
2.2. HTS Neuro-Oncology Gene Panel. A published HTS
DNA-based panel that uses targeted enrichment to examine
exonic, selected intronic and promoter regions of 130 clini-
cally relevant neuro-oncology genes was utilised (see Table S2)
[30]. 0e diagnostic panel has been optimised for use either
with fresh-frozen or FFPE tissue. Validation studies of the
HTS panel analysing ∼200 single nucleotide variants (SNVs),
gene fusions, and copy number variants (CNVs) showed 98%
concordance with single marker tests [30]. Using the HTS
panel, genetic alterations in tumours were characterized, and
TERT promoter and IDH1/2 status confirmed.
2.3. DNA Extraction, HTS Library Preparation, Sequencing,
and Analysis. Slides were deparaffinised and rehydrated
using xylene and ethanol and left to dry. Tissue sections were
then microdissected and placed into 180 uL ATL buffer.
DNA was extracted from tissue sections (10×10 μm)
according to manufacturer’s instructions using the QIAamp
DNA FFPE Tissue Kit (Qiagen, Manchester, UK). Following
assessment of DNA quality and quantity, libraries were
prepared using 200 ng of genomic DNA with an optical
density 260/280 ratio between 1.8 and 2.0. Libraries were
constructed using the SureSelectXT Target Enrichment
System for Illumina Paired-End Multiplexed Sequencing
Library protocol (Agilent). PCRmaster mixes were prepared
using the SureSelectXT Library Prep Kit ILM following
manufacturer’s guidelines. In accordance with Illumina
guidelines, libraries with a concentration of 4 nM were di-
luted to 20 pM, denatured, and sequenced on a NextSeq 500
(Illumina). HTS data were analysed following the pipeline
described by Sahm et al. [30]. In brief, raw reads were
demultiplexed, converted to fastq, quality checked, and
manually trimmed when necessary. Paired-end reads were
aligned to the human genome (version GRch37; hg19), and
duplicate sequences were removed.
2.4. CNV Analysis in the GBM Cohort. CNVs were investi-
gated using a coverage analysis. 0e ratio of on- and off-
target reads, coverage per target region, and mean coverage
per sample were estimated using the R package TEQC [32].
Measures provided an estimate of read depth, as the number
of reconstructed strands across a region of interest, and this
was utilised for CNV estimation of genes. Data normal-
isation and CNV comparison to a reference control were
made using the R package seqCNA [33]. 0is method has
previously been validated with 100% concordance for 47
GBM cases using 450 k data [30]. Potential CNV gain or loss
is indicated by deviations from a proportional read depth of
50%, considered a normal gene copy number.
Table 1: Summary of the clinical data for patients genomically
profiled in this study (n� 41). Patients with IDH-wildtype and
IDH-mutant glioblastoma tumours were identified from the
BRASH clinical database between 2009 and 2014.
Characteristic IDH-wildtype IDH-mutant
Number of patients 38 3
Age
Mean 54 42
Median (range) 52 (16–78) 50 (19–58)
Gender
Male 19 (50%) 2 (66%)
Female 20 (50%) 1 (33%)
Survival range (months) 2–48 5–12
Tumour location
Temporal lobe 8 (21%) 2 (66%)
Frontal lobe 15 (39%)
Parietal lobe 4 (11%)
Occipital 4 (11%)
More than one lobe 5 (13%) 1 (33%)
Multifocal 1 (3%)
No data 1 (3%)
Tumour recurrence
Initial 38 3
Recurrent 7 1
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2.5. SNV Analysis in the GBM Cohort. Variant calling fol-
lowed a modified pipeline, as described by Sahm et al. [30].
In brief, variants were called using SAMtools mpileup [34].
Variant calls were then filtered by (a) read depth≥ 40, (b)
genotype quality≥ 99, (c) minimum allele frequency set at
10, and (d) at least 10% read coverage from each strand using
the R package VariantAnnotation [35]. TERT promoter
position calls were not filtered due to their low detection rate
because of difficulties with their amplification as a GC-rich
region [30]. Nonsynonymous filtered variants were anno-
tated with the most up to date information including dbSNP
and COSMIC identifiers using the online tool wANNOVAR
[36]. Matched normal tissue was unavailable for comparison
for the identification of germline mutations. 0us, to try to
discern pathogenic from benign variants, the frequency of a
variant in the general population was used as a key criterion
in their clinical interpretation to try to exclude germline
mutations. SNVs were filtered to those with a frequency of≥0.01 in the 1,000 Genomes database and ≥0.05 in the
Genome Aggregation Database (gnomAD), previously
known as the Exome Aggregation Consortium database.
gnomAD warehouses whole genome sequences from 15,496
unrelated individuals [37]. As the ethnicity of patients in the
GBM cohort was unknown, SNV frequencies were com-
pared to overall frequencies (rather than regional) of both
databases. Filtered SNVs impacting genes were categorised
into biological pathways using GeneCards [38]. SNVs oc-
curring in the potentially clinically actionable genes: EGFR,
PTEN, CDKN2A, RB1, TP53, ATM, ATR, MSH6, PDGFRA,
PIK3CA, PIK3R1, SMO, PTCH1, BRCA1, BRCA2, and
BRAF, were quantified in the initial and matched recurrent
tumours. Further filtering was applied to SNV results to try
to identify variants of unknown significance (VUS) that are
possibly pathogenic and underpin gliomagenesis. VUS
considered to be possibly pathogenic, were those that had no
frequency recorded in the 1,000 Genomes database, and
were predicted to be damaging by both LJB SIFT and
FATHMM-MKL software [39]. All genomic positions listed
for SNVs identified by this study are from the human ge-
nome version GRch37.
2.6. VUS and CNV Analysis in the TCGA-GBM and GDC
Datasets. VUS identified as possibly pathogenic mutations
in the GBM cohort were further investigated for supporting
evidence of their clinical significance using TCGA-GBM and
GDC datasets. Frequencies of cases with mutations in genes
were investigated in the GDC data portal. Abundance of
mutations and copy number alterations within the TCGA-
GBM dataset was visualised as an oncoprint plot generated
using GlioVis, a data visualisation tool for brain tumour
datasets [40].
2.7. Survival Analyses of IDH-Wildtype Glioblastomas. A
Cox proportional hazard regression analysis was imple-
mented to determine the relationship between the total
number of SNVs (median split) and overall survival.MGMT
methylated and unmethylated GBMs were investigated
separately. Survival analyses and plotting of results as
Kaplan–Meier graphs were carried out using R software [41].
Of the 41 patients, univariate survival analysis was carried
out on the 33 IDH-wildtype patients only. Omitted patients
included the three IDHMUT patients and a further five pa-
tients lacking survival information.
3. Results
3.1. Overview of Genomic Profiling of Glioblastoma Tumours
and IDH Status. In all, 49 samples from 41 patients in-
cluding 8 matched samples were genomically profiled (Ta-
bles 1 and S1). Results could not be obtained for 5 initial and
13 recurrent samples from 11 patients, giving a sequencing
failure rate of ∼22%. SNVs were not identified in 5 samples
(9%). Recurrent tumour samples were necrotic with low
cellularity, which probably impacted DNA quality and se-
quencing success. Majority of tumours were IDH-wildtype
(38/41; 93%) with the exception of three cases (8, 35, and 39)
that were IDH-mutant (Table S1). Cases 8, 35, and 39 had a C
to Tmutation located at the IDH1 diagnostic hotspot R132
(Chr2: 209113112; GRCh37). Only one other case (6a) had
an IDH1 mutation located at Chr2: 209108284 (GRCh37).
0is mutation was 4,828 bp upstream of the diagnostic
hotspot (R132); hence, case 6a was considered IDH-wild-
type. One case had an IDH2 mutation (Chr15: 90627553);
however, this did not coincide with known somatic muta-
tions located at 15q26.1 codons R140 (Chr15: 90631934) and
R172 (Chr15: 90631837). TERTmutations were observed in
IDH wildtype initial (Chr5: 1254594; Chr5: 1294166) and
recurrent tumours (Chr5: 1,254,594); however, none coin-
cided with known somatic mutations in promoter regions at
the C228 (Chr5: 1,295,228) and C250 loci (Chr5: 1,295,250;
hg19).
3.2. SNVs Detected in Initial and Recurrent IDHWT
Glioblastomas. A total of 134 nonsynonymous and three
stop-gain SNVs were detected from initial (n� 125; Table S4)
and recurrent IDHWT tumours (n� 12; Table S5). Including
IDH1/2 mutations, SNVs affected 52 genes across nine bi-
ological pathways during the different phases of glioma-
genesis (Figures 1 and 2; Tables 2 and 3). Majority of
initial tumours had SNVs in a gene in the RTK/Ras/PI(3)K
pathways (79%; 30/38) followed by the p53 DNA
damage repair pathway (61%; 23/38). Two stop-gain SNVs
were identified from the p53 genes MSH2 (Chr2: 47705428;
rs63751155) and TP53 (Chr17: 7579315; COSM326717;
COSM3388232; COSM326718; COSM3388233; COSM326716)
in initial tumours; both variants were predicted to be path-
ogenic by FATHMM-MKL (Table S4). A large proportion of
initial IDHWT tumours had SNVs in the p53 pathway genes
BRCA1 (18%; 7/38) and BRCA2 (18%; 7/38; Table 4). Six
BRCA1 variants were detected including a confirmed somatic
mutation in adenocarcinoma (COSM6612515; Chr17:
41244952) [42]. Six BRCA2 variants were detected including
confirmed somatic mutations in haemangioblastoma
(COSM3753648, Chr13: 32914236; COSM5019704, Chr13:
32953549) [43]. Over half of initial IDHWT tumours had an
SNV in a WNT signalling pathway gene (58%; 22/38).
Journal of Oncology 3
Genes 1a 2a 3a 4a 5a 6a 7a 9a 10a 11a 16a 17a 18a 19a 20a 21a 22a
IDHWT IDHMUT
23a 24a 25a 26a 27a 28a 29a 30a 31a 32a 33a 34a 36a 37a 38a 40a 41a 43a 44a 45a 46a 8a 35a 39a
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RAD50
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CDKN2A
CDK6
RB1
GNAS
Figure 1: Summary of the genes identified with SNVs in IDHWT (n� 38) and IDHMUTdiffuse tumours (n� 3; cases 8a, 35a, and 39a). Genes are
arranged hierarchically within their pathways for the RTK/Ras/PI(3)K (red), IDH (yellow), NOTCH, SHH, andWNTsignalling (variations of
green), p53 (blue), Rb (purple), and G-proteins (dark blue) pathways. Numbers across the top axis denote the patient identifier.
Genes 1a 1b 2a 2b 3a 3b 4a 4b 5a 5b 7a 7b 36a 36b 8a 8b
PIK3CA
PIK3R1
NTRK2
EGFR
FGFR2
FGFR3
FGFR4
PDGFRA
ALK
MET
MYB
BRAF
CSF1R
PTEN
JAK2
JAK3
KDR
KLK1
LZTR1
CDH1
DAXX
FOXO3
TSC2
IDH1
IDH2
NOTCH1
NOTCH2
PTCH1
PTCH2
SMO
KLF4
APC
CREBBP
TERT
KMT2D
DICER1
ATR
ATM
BRCA1
BRCA2
CHEK2
MSH2
MSH6
PPM1D
RAD50
BRPF3
MDM4
TP53
CDKN2A
CDK6
RB1
GNAS
IDHWT IDHMUT
Figure 2: Summary of the genes identified with SNVs in matched initial and recurrent IDHWT (n� 7) and IDHMUTdiffuse tumours (n� 1;
case 8). Genes are arranged hierarchically within their pathways for the RTK/Ras/PI(3)K (red), IDH (yellow), NOTCH, SHH, and WNT
signalling (variations of green), p53 (blue), Rb (purple), and G-proteins (dark blue) pathways. Numbers across the top axis denote the
patient identifier; “a” and “b” indicate initial and recurrent tumours, respectively.
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Multiple variants (n) were detected for the WNT genes
KMT2D/MLL2 (7), CREBBP (4), DICER1 (3), APC (3), TERT
(2), and KLF4 (2). IDHWT tumours also showed variation in
SHH (16%; 6/38) and NOTCH (8%; 3/38) pathways. A small
proportion of initial tumours had SNVs in the G-protein
gene, GNAS (5%; 2/38), IDH1/2 (5%; 2/38), and the Rb-
specific cell-cycle regulation genes CDK6 and RB1 (5%; 2/38).
0e RB1 variant was a stop-gain SNV (Chr13: 48953735), but
it was not pathogenic. Among IDHWTtumours, 40 SNVs in 21
genes were VUS that were predicted to be functionally
damaging (Tables 3 and S3). Potentially pathogenic VUS
impacted IDH1 and genes in the p53 (ATM, BRCA1, CHEK2,
MSH6, PPM1D, and TP53), RTK/Ras/PI(3)K (BRAF, DAXX,
EGFR, FGFR2, JAK2, MYB, PIK3CA, PIK3R1, TSC2, and
PTEN), SHH (PTCH1 and SMO), and WNT pathways
(CREBBP). Two-thirds of initial IDHWT tumours (63%; 24/
38) harboured potentially actionable variation most fre-
quently in PTEN (29%; 11/38), followed by BRCA1 (18%; 7/
38), BRCA2 (18%; 7/38), TP53 (18%; 7/38), EGFR (16%; 6/38),
ATM (16%; 6/38), and ATR (8%; 3/38; see Table 4). Recurrent
IDHWT tumours had SNVs in genes in the RTK/Ras/PI(3)K
(43%; 3/7), WNT signalling (57%; 4/7), and p53 pathways
(29%) in the genes BRCA1 (14%; 1/7) and BRCA2 (14%; 1/7)
and GNAS (14%; 1/7). IDHWT recurrent tumours were not
mutated in NOTCH, SHH, Rb, or IDH genes (Figure 2 and
Table S5). In the matched initial tumour, 16 genes showed
variation, four of which were also mutated in the recurrent
tumour. An additional three SNVs were recorded only in the
recurrent tumour in CSF1R, ATM, and BRCA1. Possibly
pathogenic VUS were identified in PTEN in recurrent IDHWT
tumours. Almost half of recurrent IDHWTtumours (43%; 3/7)
harboured at least one potentially actionable variation in the
genes EGFR (14%; 1/7), PTEN (14%; 1/7), BRCA1 (14%; 1/7),
BRCA2 (14%; 1/7), and ATM (14%; 1/7; Figure 2 and Table 4).
3.3. SNVs Detected in Initial and Recurrent IDHMUT
Glioblastomas. SNVs detected in IDHMUT initial (n� 12)
and recurrent tumours (n� 1; Tables S4, and S5) impacted
IDH1 and 10 genes across 5 biological pathways (Figures 1
and 2; Table 2). Majority of initial tumours had SNVs in
genes in the RTK/Ras/PI(3)K (66%; 2/3), followed by p53
(100%; 3/3) and WNT signalling pathway (33%; 1/3). All
initial IDHMUT tumours (100%; 3/3) harboured at least one
potentially actionable variation in TP53 (100%; 3/3), BRCA2
(33%; 1/3), and MSH6 (33%; 1/3; Table 4). Just 7 SNVs in 6
genes were VUS that were possibly pathogenic in IDHMUT
initial tumours. 0ese included IDH1 and the p53 pathway
genesMSH6 and TP53 and the RTK/Ras/PI(3)K genes KLK1
and TSC2 and the CREBBP gene in the WNT pathway
(Table 3). 0e KLK1 variant was potentially pathogenic in
IDHMUT but not in IDHWT. 0e recurrent IDHMUT tumour
had SNVs in p53, WNT signalling, and G-protein pathway
genes. Matched analysis revealed that seven genes had SNVs
in the initial that were not observed in the recurrent tumour
(Figure 2). 0e recurrent tumour had SNVs in one gene not
recorded in the initial (GNAS). No genes had SNVs that were
potentially actionable in the recurrent IDHMUT tumour
(Table 4).
3.4.CNVs in IDHWTandIDHMUTGlioblastomas. CNVs were
detected in IDHWT tumours only (Table S6). 0e results for
CNVs in the corresponding genes in TCGA-GBM are
presented in Figure S1. For sample 36, there appears to be a
hemizygous deletion in BRCA2 in the initial, but a CNV gain
in the recurrent tumour. Both trends were identified in
TCGA-GBM, but predominantly BRCA2 had shallow de-
letions.0ere were CNV gains inGNAS for recurrent sample
3b. TCGA-GBM results also predominantly indicate CNV
gains for GNAS. In recurrent samples 1b and 7b, TERT
appeared to have hemizygous deletions. TCGA-GBM had
both TERT CNV losses and gains with no predominant
trend evident. For SMARCA4, there appears to be a CNV
gain in initial sample 1 but a hemizygous deletion in the
recurrent sample. TCGA-GBM had mostly CNV gains with
some losses for SMARCA4. Significant CNV gains in EGFR
were observed for initial and recurrent sample 2 and sim-
ilarly in TCGA-GBM cases.
3.5. Investigation of the Corresponding Genes (withMutations
and CNVs in the GBM Cohort) in the TCGA-GBM and GDC
Datasets. 0e results of investigations in the TCGA-GBM
and GDC datasets for the 21 genes identified with VUS that
were possibly pathogenic in the GBM cohort are presented
in Figure S2. A summary of SNVs identified from those
corresponding genes in the TCGA-GBM dataset is provided
in Table S7. TCGA-GBM cases in themutation data included
6 verified and 2 ambiguous IDH-mutant individuals;
however, majority of cases are unannotated. PTEN was the
Table 2: Summary of the number and proportion of IDH-wildtype and IDH-mutant glioblastoma patients with SNVs in genes in the RTK/
Ras/PI(3)K, p53 DNA damage repair, WNT signalling, SHH, NOTCH, Rb, and G-protein pathways.
Pathway
IDH-wildtype IDH-mutant
Initial Recurrent Initial Recurrent
% N % N % N % N
RTK/Ras/PI(3)K 79 30/38 43 3/7 66 2/3 0 0/1
p53 DNA damage repair 61 23/38 29 2/7 100 3/3 100 1/1
WNT signalling 58 22/38 57 4/7 33 1/3 100 1/1
SHH 16 6/38 0 0/7 0 0/3 0 0/1
NOTCH 8 3/38 0 0/7 0 0/3 0 0/1
Rb 5 2/38 0 0/7 0 0/3 0 0/1
G-protein 5 2/38 14 1/7 0 0/3 100 1/1
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Table 3: Comparison of genes with SNVs identified in IDH-wildtype and IDH-mutant initial and recurrent tumours in the GBM cohort
with those outlined by Barthel et al. [8], described for the five phases of gliomagenesis.
Gliomagenesis
phases Pathway
Common
tumour genetic
alterations
(Barthel et al.)
IDH wildtype IDH-mutant
Barthel
et al.
GB-
initial
GB-
recurrent
GB-
potentially
pathogenic
VUS
Barthel
et al.
GB-
initial
GB-
recurrent
GB-
potentially
pathogenic
VUS
Diagnostic
panel (Y/
N)
I: initial growth
IDH — IDH1 — Y IDH1 IDH1 — Y Y
IDH — IDH2 — IDH2 — — Y
Rb CDK6 CDK6 — — — — Y
RTK/
Ras/
PI(3)K
EGFR EGFR EGFR Y — — — Y
RTK/
Ras/
PI(3)K
MET MET — — — — Y
RTK/
Ras/
PI(3)K
PDGFRA PDGFRA — PDGFRA — — Y
RTK/
Ras/
PI(3)K
PIK3CA PIK3CA — Y — — — Y
RTK/
Ras/
PI(3)K
PIK3R1 PIK3R1 — Y — — — Y
RTK/
Ras/
PI(3)K
PTEN PTEN PTEN Y — — — Y
WNT TERT TERT TERT — — — Y
NF1 — — — — — Y
CTCF N
TET1 N
II: oncogene-
induced
senescence
p53 TP53 TP53 TP53 — Y TP53 TP53 — Y Y
p53 CDKN2A CDKN2A CDKN2A — — — — Y
p53 PPM1D PPM1D — Y — — — Y
Rb RB1 RB1 — — — — Y
RTK/
Ras/
PI(3)K
BRAF BRAF — Y — — — Y
CDKN2B CDKN2B — — — — — Y
ACVR1 — — — — — Y
III: stressed
growth
p53 ATM ATM ATM Y — — Y
p53 ATR ATR — Y — — — Y
MYC — — — — — Y
CDK4 — — — — — Y
MDM2 — — — — — Y
IV: replicative
senescence/crisis
CHD5 N
TREX1 N
Terra N
RB1 — RB1 — — — — Y
WNT TERT TERT TERT TERT — — — Y
p53 TP53 TP53 TP53 — Y TP53 TP53 — Y Y
ATRX - — ATRX — — Y
— DAXX — Y DAXX — — Y
V:
immortalisation
and
dedifferentiation
OLIG2 N
SOX2 N
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Table 3: Continued.
Gliomagenesis
phases Pathway
Common
tumour genetic
alterations
(Barthel et al.)
IDH wildtype IDH-mutant
Barthel
et al.
GB-
initial
GB-
recurrent
GB-
potentially
pathogenic
VUS
Barthel
et al.
GB-
initial
GB-
recurrent
GB-
potentially
pathogenic
VUS
Diagnostic
panel (Y/
N)
GB-SNVs
G-
proteins — GNAS GNAS — — GNAS Y
NOTCH — NOTCH1 — — — — Y
NOTCH — NOTCH2 — — — — Y
p53 — BRCA1 BRCA1 Y — — — Y
p53 — BRCA2 BRCA2 — BRCA2 — Y
p53 — BRPF3 — — — — Y
p53 — MDM4 — — — — Y
p53 — MSH2 — — MSH2 — Y
p53 — MSH6 — Y — MSH6 — Y Y
p53 — RAD50 — — — — Y
RTK/
Ras/
PI(3)K
— ALK — — — — Y
RTK/
Ras/
PI(3)K
— CDH1 — — CDH1 — Y
RTK/
Ras/
PI(3)K
— CSF1R CSF1R — CSF1R — Y
RTK/
Ras/
PI(3)K
— FGFR2 — Y — — — Y
RTK/
Ras/
PI(3)K
— FGFR3 — — — — Y
RTK/
Ras/
PI(3)K
— FGFR4 — — — — Y
RTK/
Ras/
PI(3)K
— FOXO3 — — — — Y
RTK/
Ras/
PI(3)K
— JAK2 — Y — — — Y
RTK/
Ras/
PI(3)K
— KDR KDR — — — Y
RTK/
Ras/
PI(3)K
— KLK1 — — KLK1 — Y Y
RTK/
Ras/
PI(3)K
— LZTR1 — — — — Y
RTK/
Ras/
PI(3)K
— MYB — Y — — — Y
RTK/
Ras/
PI(3)K
— NTRK2 — — — — Y
RTK/
Ras/
PI(3)K
— TSC2 — Y — TSC2 — Y Y
SHH — PTCH1 — Y — — — Y
SHH — PTCH2 — — — — Y
SHH — SMO — Y — — — Y
WNT — APC — — APC — Y
WNT — CREBBP — Y — CREBBP — Y Y
WNT — DICER1 — — — — Y
WNT — KLF4 — — — — Y
WNT — KMT2D — — — — Y
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gene most impacted by mutations (34.86%) and shallow or
deep deletions (Table S8; Figure S2). EGFR had mutations
(26.97%) and CNV gains. FGFR2 (1.53%), JAK2 (1.27%),
MYB (1.27%), and ATM (2.04%) had fewer mutations and
mostly shallow or deep deletions. Both BRAF (2.54%) and
SMO (1.02%) had fewer mutations and mostly low level
CNV gains. TP53 (31.55%), PIK3CA (10.18%), and PIK3R1
(10.94%) had relatively high mutations and a mixture of
CNV gains and deletions. IDH1 (6.62%), BRCA1 (2.8%),
PTCH1 (3.56%), CREBBP (3.56%), MSH6 (3.05%), DAXX
(2.29%), TSC2 (2.04%), PPM1D (1.78%), KLK1 (0.51%), and
CHEK2 (0.25%) had low rate of mutations and a mixture of
CNV low level gains and losses. BRCA1 (2.8%) had low rate
of mutations and both CNV low level gains and shallow or
deep deletions. 0e results for the 12 NOTCH, SHH, and
WNT pathway genes identified to be impacted in the GBM
cohort investigated in the TCGA-GBM and GDC datasets
are presented in Table S9 and Figure S3. 0e WNTpathway
genes DICER1 (2.29%), KLF4 (0.25%), and CREBBP (3.56%)
had mutations and CNV shallow deletions, as well as low
level gains and high level amplifications. TERT (2.80%) and
KMT2D (3.05%) had mutations and CNV shallow gains and
losses as well as deep deletions. APC (4.58%) and TCF4
(0.76%) had mutations, low level gains, and shallow dele-
tions. 0e SHH genes, PTCH1 (3.56%), PTCH2 (1.78%), and
SMO (1.02%) were impacted by mutations. Whilst the SMO
gene had CNV gains, by comparison, the PTCH1 and
PTCH2 genes had both CNV gains and losses. NOTCH
genes, NOTCH2 (4.07%) and NOTCH1 (0.25%), had mu-
tations and were impacted also by gains and losses in CNV.
3.6. Impact of SNV Burden on Survival in IDHWT GBM
Patients. 0e number of tumour SNVs was prognostic for
survival in methylated GBM patients (log rank� 7.63, 95%
CI� 6.90–27.10; P value� 0.006, two-sided). Median survival
for methylated GBMwith≤ 4 SNVs was 23months compared
to amedian survival of 10months for a tumour with≥ 5 SNVs
(Figure 3; Table S10). For unmethylated GBM patients, the
number of tumour SNVs was not prognostic for survival (log
rank� 3.393, 95% CI� 9.441–12.559; P value� 0.065).
Median survival was 13 months for unmethylated GBMs
with≤ 4 SNVs, compared to a median survival of 11 months
for≥ 5 SNVs (Figure 4; Table S10). Sample sizes were rela-
tively small in these survival analyses; therefore, the observed
trends would need to be confirmed using a larger cohort.
4. Discussion
0emutational landscape of the GBM subtypes in this cohort
raises the possibility of new combinations of therapeutic
approaches for individual GBM patients. Potentially ac-
tionable variation was most often identified in EGFR, PTEN,
BRCA1/2, and ATM. 0ese genetic alterations could be
targeted by novel approaches with EGFR-targeting anti-
bodies, tyrosine kinase inhibitors, and DNA damage repair
inhibitors either singly or in combination. In particular, the
BRCA1/2 mutations raise the possibility that DNA damage
repair agents may be an option for small numbers of GBM
patients in combination with other agents. Administering
olaparib PARP (poly (ADP-ribose) polymerase) inhibitor,
developed for BRCA1/2 mutated ovarian cancer, in combi-
nation with TMZ has shown promising results for treating
relapsed glioblastoma patients in a phase I clinical trial
(NCT01390571) [44]. However, patient selection to date has
not been based on detailed molecular profiling with HTS. In
this study’s GBM cohort, both IDHWTand IDHMUTGBMhad
VUS that were predicted to be pathogenic in MSH6 [45–47],
CREBBP [48–52], TP53 [17, 47], and TSC2 [36–43, 53]. In
particular, MSH6 (MutS homolog 6) is a DNA mismatch-
repair protein that has been identified as a putative driver
gene in glioma [45, 47]. Similarly, MSH6 may be involved in
acquired resistance to alkylating agents [46]. Moreover,
CREBBP (CREB binding protein gene/CBP) activates the
DNA damage response and repair pathway by acetylating
factors involved in base excision repair, nucleotide excision
repair, nonhomologous end joining, and double-strand break
repair (e.g., PARP-1, H2AX, and NBS1) [49].
4.1. IDHWT Glioblastomas. In IDHWT glioblastomas, SNVs
impacted genes in the RTK/Ras/PI(3)K (79%), p53 (61%),
Table 3: Continued.
Gliomagenesis
phases Pathway
Common
tumour genetic
alterations
(Barthel et al.)
IDH wildtype IDH-mutant
Barthel
et al.
GB-
initial
GB-
recurrent
GB-
potentially
pathogenic
VUS
Barthel
et al.
GB-
initial
GB-
recurrent
GB-
potentially
pathogenic
VUS
Diagnostic
panel (Y/
N)
Risk mutations
related to
heritable diseases
(Barthel et al. [8])
TERC N
OBFC1 N
POT1 N
RTEL1 N
TERT TERT TERT TERT — — — Y
TP53 TP53 TP53 — Y TP53 TP53 — Y Y
NF1 — — — — — — Y
NF2 — — — — — — Y
CHK2
(CHEK2) — CHEK2 — Y — — — Y
Also included is a list of risk mutations related to heritable diseases. Genes identified with VUS that were possibly pathogenic in the GBM cohort are
highlighted in bold.
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WNT (58%), SHH (16%), NOTCH (8%), Rb (5%) and
G-protein (5%) pathways. Potentially actionable mutations
detected from initial IDHWTtumours included EGFR, PTEN,
BRCA1, BRCA2, ATM, and ATR [54–56]. 0erapies for this
subtype might include the EGFR-targeting antibodies,
EGFR-targeting vaccines, TK inhibitors, erlotinib, and DNA
damage repair inhibitors including olaparib and ATR in-
hibitors. Anti-EGFR-targeting antibodies to date have not
shown clinical efficacy in GBM although trials are ongoing
[57]. Similarly, trials of DNA damage repair inhibitors are
underway, and the results are anticipated; however, patients
have not been selected for these trials using molecular
profiling with HTS.
Interestingly, in this cohort, a high proportion of IDHWT
tumours was impacted by BRCA1 (18%) and BRCA2 (18%)
mutations. 0is trend was not observed in the TCGA-GBM
dataset (2.8%; 2.3%); however, the IDH status of patients is
not confirmed in most cases [58]. Only one variant from the
GBM cohort (BRCA1 : Ch17: 41246062) was identifiable
amongst the TCGA-GBM dataset BRCA1 (n� 16) and
BRCA2 (n� 39) variants. 0e well-known breast cancer
specific germline mutations in BRCA1 (185delAG; Chr17:
43124030–43124031 and 5382insC; Chr17: 43057065) and
BRCA2 (6174delT; Chr13: 32340301) were not amongst the
variants identified in either the GBM cohort or the TCGA-
GBM cohort. In this GBM cohort, amongst the BRCA2
variants were confirmed somatic mutations in hae-
mangioblastoma (BRCA2 : COSM3753648, COSM5019704)
[43], which is a rare, benign tumour that typically occurs in
the cerebellum [3]. Many IDHWT tumours had alterations
impacting WNT [59–63] signalling pathway genes (58%)
including CREBBP(4), KLF4(2) [64, 65], TERT(2) [17], and
APC(3) [66–70]; however, targeting this pathway is currently
challenging. Initial IDHWT tumours also showed predicted
pathogenic variation in NOTCH (11%) [71] and SHH (13%)
pathways [72] including PTCH1 (PATCHED-1) and SMO
(Smoothened) [73–75].0e Hedgehog antagonist GDC-0449
(vismodegib) has been trialled in recurrent GBM
(NCT00980343) and childhood brain tumours with varying
success to date.
4.2. Recurrent IDHWT Glioblastomas. Interestingly in this
cohort, no tumours exhibited a TMZ-induced hypermutated
phenotype. Tumours did not have mutations in TERT
promoter regions. Kim et al. found that a TMZ-induced
hypermutated phenotype was rare in IDH-wildtype primary
glioblastomas [76]. Acquired resistance in glioma has been
attributed to dysregulated pathways (signalling and DNA
repair), persistence of cancer stem cell subpopulations, and
autophagy mechanisms [77]. In this cohort, only the RTK/
Ras/PI(3)K, p53 DNA damage repair, WNT signalling, and
G-protein pathways were impacted by genetic alterations
and not the SHH, NOTCH, and Rb pathways, despite their
association with glioma resistance. Whilst fewer pathways
were impacted, intertumour heterogeneity between initial
and recurrent IDH wildtype tumours was nevertheless ob-
served, similar to previous studies [76, 78]. Indeed, recurrent
tumours can diverge to such an extent that they are no
longer recognised as lineal descendants of the dominant
clone identified initial at diagnosis [78, 79]. Potential sig-
natures of IDHWT recurrent tumour resistance included
VUS that were possibly pathogenic in PTEN. PTEN mu-
tations cause activation of the PI3K/AKT survival pathway
and chemoresistance in GBM [80]. Other possible signatures
of recurrent tumour resistance in this GBM cohort included
CNV gains in the genes (chromosome), BRCA2 (Chr13),
GNAS (Guanine nucleotide-binding protein G(s) subunit
alpha; Chr20), and EGFR (Chr7). Copy number gains are
thought to impact driver genes to initiate tumourigenesis.
0e oncogene EGFR is located on chromosome 7, which
frequently has CNV gains in IDH-wildtype glioblastomas
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Figure 3: Comparison of survival for IDHWTglioblastomaMGMT
methylated patients with high versus low total number of tumour
SNVs, based on a median split. Kaplan–Meier analysis indicates
that IDHWTGBM patients with a greater tumour SNV burden have
significantly a shorter overall survival (P � 0.006).
Unmethylated
0.0
0.2
0.4
0.6
0.8
1.0
Cu
m
ul
at
iv
e s
ur
vi
va
l
10 20 30 400
Survival time (months)
Total count
Censored
≤4
≥5
Figure 4: Comparison of survival for IDHWTglioblastomaMGMT
unmethylated patients with high versus low total number of tu-
mour SNVs, based on a median split. Kaplan–Meier analysis in-
dicates that IDHWT GBM patients with a greater tumour SNV
burden have a shorter overall survival; however, this trend was not
significant (P � 0.065).
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(∼70%) [5, 6]. Gains in the chromosome 20 arm containing
GNAS are frequently observed in pituitary brain tumours
(adenomas) and may exert a mitogenic influence on the
WNT signalling pathway via cAMP activation, which may
provide a proliferative advantage for resistance [81].
However, GNAS has not been identified as a prognostic in
dicator implicated in GBM [82]. CNV losses observed in
the GBM cohort included SMARCA4 (Chr19) [47] and
TERT (Chr5). CNV losses may be concordant with gene
expression downregulation [83].
4.3. IDHMUT Glioblastomas. Results for IDHMUT glioblas-
tomas comprised three initial and one recurrent case only.
Pathways impacted by genetic alterations included the RTK/
Ras/PI(3)K (66%), p53 (100%), and WNT pathways (33%).
Possibly pathogenic VUS identified herein included those
co-mutated in both subtypes as well as KLK1 (kallikrein1).
0e kallikreins KLK6, KLK7, and KLK9 have been shown to
have higher protein levels in Grade IV glioma compared to
Grade III tumours and consequently may have utility as
prognostic markers for patient survival [84]. All initial
IDHMUT tumour samples harboured potentially actionable
variation in at least one of the genes TP53, BRCA2, and
MSH6. 0e recurrent tumour had fewer pathways (p53,
WNT, and G-protein) impacted by genetic alterations.
Matched analysis revealed intertumour heterogeneity. 0e
recurrent IDHMUT tumour lacked potentially actionable
variation that could be targeted. Given the small sample size
for this subtype all trends reported here would need to be
confirmed in a larger cohort.
5. Conclusion
Our study reveals that matched initial and recurrent GBM
samples harbour potentially actionable variations, and these
were most often identified in EGFR, PTEN, BRCA1/2, and
ATM. 0ese genetic alterations could potentially be targeted
by novel approaches with EGFR-targeting antibodies, ty-
rosine kinase inhibitors, and DNA damage repair inhibitors
either singly or in combination. 0is study underlines the
need for detailed genetic analysis of GBM patients to identify
individuals that might benefit from novel therapeutic ap-
proaches that are becoming available in the near future. 0is
information is also important for patient recruitment to
clinical trials.
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Supplementary Materials
Figure S1: oncoprint plot of mutations and copy number
alterations identified in the TCGA-GBM dataset for 8
corresponding genes impacted by CNVs in the GBM cohort.
Genes are represented as rows, and individual patients are
represented as columns. 0e right barplot displays the
number and type of alterations to each gene, categorised as
AMP: high level amplification, GAIN: low level gain,
HETLOSS: shallow deletion, HOMDEL: deep deletion, and
MUT: SNV mutation event (green). Figure S2: oncoprint
plot of mutations and copy number alterations identified in
the TCGA-GBM dataset for the 21 corresponding genes
impacted by VUS that were possibly pathogenic in the GBM
cohort. Genes are represented as rows, and individual pa-
tients are represented as columns. 0e right barplot displays
the number and type of alterations to each gene, categorised
as AMP: high level amplification, GAIN: low level gain,
HETLOSS: shallow deletion, HOMDEL: deep deletion, and
MUT: SNV mutation event (green). Figure S3: oncoprint
plot of mutations and copy number alterations identified in
the TCGA-GBM dataset for 12 WNT/Notch/SHH pathway
genes impacted by SNVs in the GBM cohort. Genes are
represented as rows, and individual patients are represented
as columns. 0e right barplot displays the number and type
of alterations to each gene, categorised as AMP: high level
amplification, GAIN: low level gain, HETLOSS: shallow
deletion, HOMDEL: deep deletion, and MUT: SNV muta-
tion event (green). Table S1: demographic data for the IDH-
wildtype (n� 38) and IDH-mutant glioblastomas. Clinical
records are for case ID, age, sex, tumour location on theMRI
scan, IDH1 R132H hotspot mutation status, patient survival
in months, and samples with matched initial and recurrent
tumours. Table S2: list of the clinically relevant neuro-on-
cology genes that were analysed by the HTS-based diag-
nostic panel used in this study that was developed in
Ruprecht Karl-University Heidelberg, Germany (see Sahm
et al. [30]). Table S3: summary of the possibly pathogenic
VUS identified in initial and recurrent IDH-wildtype and
IDH-mutant glioblastoma tumours. 0e exonic non-
synonymous SNVs were predicted to be damaging by both
LJB SIFT and FATHMM-MKL tools and had not been
recorded by the 1000G database. Descriptive information for
tumour, IDH status, genomic position, affected gene and
pathway, available dbSNP and COSMIC identifiers,
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functional impacts predicted by LJB SIFT and FATHMM-
MKL, and a shortened description from InterPro domain are
provided. NA; not applicable (see Supplementary Tables
Excel File). Table S4: summary of SNVs identified in initial
tumours. Descriptive information for tumour, IDH status,
genomic position, reference, and alternative variant alleles,
affected gene, and pathway, ClinVar significance, functional
impacts as predicted by LJB SIFT and FATHMM-MKL and
available dbSNP and COSMIC identifiers and InterPro
domain description are provided (see Supplementary Tables
Excel File). Table S5: summary of SNVs identified in re-
current tumours. Descriptive information for tumour, IDH
status, genomic position, reference and alternative variant
alleles, affected gene and pathway, ClinVar significance,
functional impacts as predicted by LJB SIFTand FATHMM-
MKL and available dbSNP and COSMIC identifiers and
InterPro domain description are provided (see Supple-
mentary Tables Excel File). Table S6: summary of CNVs
identified in initial and recurrent IDH-wildtype glioblas-
tomas. CNV estimation is based on the read depth (%) of the
variant (V) compared to a reference control (R; see
Methods). Table S7: summary of the SNVs in TCGA-GBM
dataset identified for the corresponding genes with VUS that
were possibly pathogenic in the GB cohort. Descriptive
information for tumour sample, gene, mutation type, amino
acid change, genomic position, reference, and alternative
variant alleles is provided (see Supplementary Tables Excel
File). Table S8: number of cases in TCGA-GBM and GDC
mutation datasets affected by mutations in the genes
identified to have VUS that are possibly pathogenic in the
GB cohort. According to TCGA, a total of 393 cases were
tested for somatic mutations. TCGA-GBM comprises a
small number of verified (n� 6) and ambiguous IDH-mu-
tant cases (n� 2; see ). Table S9: number of cases in TCGA-
GBM and GDC datasets affected by mutations in the WNT,
notch, and SHH genes identified to have somatic mutations
in the GB cohort. Table S10: mean and median survival time
results of the survival analyses to test the impact of SNV
burden on overall survival in MGMT methylated and
unmethylated IDH-wildtype GBMs. (Supplementary
Materials)
References
[1] N. G. Burnet, S. J. Jefferies, R. J. Benson, D. P. Hunt, and
F. P. Treasure, “Years of life lost (YLL) from cancer is an
important measure of population burden- and should be
considered when allocating research funds,” British Journal of
Cancer, vol. 92, no. 2, pp. 241–245, 2005.
[2] Q. T. Ostrom, H. Gittleman, J. Xu et al., “CBTRUS statistical
report: primary brain and other central nervous system tu-
mors diagnosed in the United States in 2009–2013,” Neuro-
oncology, vol. 18, no. suppl_5, pp. v1–v75, 2016.
[3] D. N. Louis, H. Ohgaki, O. D. Wiestler et al., WHO Classi-
fication of Tumours of the Central Nervous System, IARC
Press, Lyon, France, 4th edition, 2016.
[4] H.-B. Cheng, W. Yue, C. Xie, R.-Y. Zhang, S.-S. Hu, and
Z.Wang, “IDH1mutation is associated with improved overall
survival in patients with glioblastoma: a meta-analysis,” Tu-
mor Biology, vol. 34, no. 6, pp. 3555–3559, 2013.
[5] S. H. Bigner, J. Mark, P. C. Burger et al., “Specific chromo-
somal abnormalities in malignant human gliomas,” Cancer
Research, vol. 48, no. 2, pp. 405–411, 1988.
[6] M. Ceccarelli, F. P. Barthel, T. M. Malta et al., “Molecular
profiling reveals biologically discrete subsets and pathways of
progression in diffuse glioma,” Cell, vol. 164, no. 3,
pp. 550–563, 2016.
[7] H. Ohgaki, P. Dessen, B. Jourde et al., “Genetic pathways to
glioblastoma,” Cancer Research, vol. 64, no. 19, pp. 6892–
6899, 2004.
[8] F. Barthel, P. Wesseling, and R. G. W. Verhaak, “Recon-
structing the molecular life history of gliomas,” Acta Neu-
ropathologica, vol. 135, no. 5, pp. 649–670, 2018.
[9] L. Dang, D. W. White, S. Gross et al., “Cancer-associated
IDH1 mutations produce 2-hydroxyglutarate,” Nature,
vol. 462, no. 7274, pp. 739–744, 2009.
[10] J. R. Prensner and A. M. Chinnaiyan, “Metabolism unhinged:
IDH mutations in cancer,” Nature Medicine, vol. 17, no. 3,
pp. 291–293, 2011.
[11] Cancer Genome Atlas Research Network, “Comprehensive
genomic characterization defines human glioblastoma genes
and core pathways,”Nature, vol. 455, no. 7216, pp. 1061–1068,
2008.
[12] R. G.W. Verhaak, K. A. Hoadley, E. Purdom et al., “Integrated
genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA,
IDH1, EGFR, andNF1,” Cancer Cell, vol. 17, no. 1, pp. 98–110,
2010.
[13] C. W. Brennan, R. G. Verhaak, A. McKenna et al., “0e
somatic genomic landscape of glioblastoma,” Cell, vol. 155,
no. 2, pp. 462–477, 2013.
[14] H. Suzuki, K. Aoki, K. Chiba et al., “Mutational landscape and
clonal architecture in grade II and III gliomas,” Nature Ge-
netics, vol. 47, no. 5, pp. 458–468, 2015.
[15] Cancer Genome Atlas Research Network, “Comprehensive,
integrative genomic analysis of diffuse lower-grade gliomas,”
New England Journal of Medicine, vol. 372, no. 26,
pp. 2481–2498, 2015.
[16] D. Speidel, “0e role of DNA damage responses in p53 bi-
ology,”Archives of Toxicology, vol. 89, no. 4, pp. 501–517, 2015.
[17] J. H. Lee, J. E. Lee, J. Y. Kahng et al., “Human glioblastoma
arises from subventricular zone cells with low-level driver
mutations,” Nature, vol. 560, no. 7717, pp. 243–247, 2018.
[18] B. H. Diplas, X. He, J. A. Brosnan-Cashman et al., “0e genomic
landscape of TERT promoter wildtype-IDH wildtype glioblas-
toma,” Nature Communications, vol. 9, no. 1, p. 2087, 2018.
[19] R. Stupp, W. P. Mason, M. J. Van Den Bent et al., “Radio-
therapy plus concomitant and adjuvant temozolomide for
glioblastoma,” New England Journal of Medicine, vol. 352,
no. 10, pp. 987–996, 2005.
[20] M. Snuderl, L. Fazlollahi, L. P. Le et al., “Mosaic amplification
of multiple receptor tyrosine kinase genes in glioblastoma,”
Cancer Cell, vol. 20, no. 6, pp. 810–817, 2011.
[21] S. C. Mack and P. A. Northcott, “Genomic analysis of
childhood brain tumors: methods for genome-wide discovery
and precision medicine become mainstream,” Journal of
Clinical Oncology, vol. 35, no. 21, pp. 2346–2354, 2017.
[22] T. Tabone, H. J. Abuhusain, A. K. Nowak, W. N. Erber, and
K. L. McDonald, “Clinical outcome of glioma (AGOG)
network. Multigene profiling to identify alternative treatment
options for glioblastoma: a pilot study,” Journal of Clinical
Pathology, vol. 67, no. 7, pp. 550–555, 2014.
[23] S. H. Ramkissoon, W. L. Bi, S. E. Schumacher et al., “Clinical
implementation of integrated whole-genome copy number
12 Journal of Oncology
and mutation profiling for glioblastoma,” Neuro-oncology,
vol. 17, no. 10, pp. 1344–1355, 2015.
[24] L. Lin, D. Gaut, K. Hu, H. Yan, D. Yin, and H. P. Koeffler,
“Dual targeting of glioblastoma multiforme with a
proteasome inhibitor (Velcade) and a phosphatidylinositol 3-
kinase inhibitor (ZSTK474),” International Journal of On-
cology, vol. 44, no. 2, pp. 557–562, 2014.
[25] K. Penne, C. Bohlin, S. Schneider, and D. Allen, “Gefitinib
(IressaTM, ZD1839) and tyrosine kinase inhibitors: the wave
of the future in cancer therapy,” Cancer Nursing, vol. 28, no. 6,
pp. 481–486, 2005.
[26] D. Singh, J. M. Chan, P. Zoppoli et al., “Transforming fusions
of FGFR and TACC genes in human glioblastoma,” Science,
vol. 337, no. 6099, pp. 1231–1235, 2012.
[27] D. Rohle, J. Popovici-Muller, N. Palaskas et al., “An inhibitor
of mutant IDH1 delays growth and promotes differentiation
of glioma cells,” Science, vol. 340, no. 6132, pp. 626–630, 2013.
[28] R. G. Lerner, S. Grossauer, B. Kadkhodaei et al., “Targeting a
Plk1-controlled polarity checkpoint in therapy-resistant
glioblastoma-propagating cells,” Cancer Research, vol. 75,
no. 24, pp. 5355–5366, 2015.
[29] R. Roskoski, “Cyclin-dependent protein kinase inhibitors
including palbociclib as anticancer drugs,” Pharmacological
Research, vol. 107, pp. 249–275, 2016.
[30] F. Sahm, D. Schrimpf, D. T. W. Jones et al., “Next-generation
sequencing in routine brain tumor diagnostics enables an
integrated diagnosis and identifies actionable targets,” Acta
Neuropathologica, vol. 131, no. 6, pp. 903–910, 2016.
[31] A. Zacher, K. Kaulich, S. Stepanow et al., “Molecular diag-
nostics of gliomas using next generation sequencing of a
glioma-tailored gene panel,” Brain Pathology, vol. 27, no. 2,
pp. 146–159, 2017.
[32] M. Hummel, S. Bonnin, E. Lowy, and G. Roma, “TEQC: an R
package for quality control in target capture experiments,”
Bioinformatics, vol. 27, no. 9, pp. 1316-1317, 2011.
[33] D. Mosen-Ansorena, N. Telleria, S. Veganzones, V. la Orden,
M. Maestro, and A. M. Aransay, “seqCNA: an R package for
DNA copy number analysis in cancer using high-throughput
sequencing,” BMC Genomics, vol. 15, no. 1, p. 178, 2014.
[34] H. Li, B. Handsaker, A. Wysoker et al., “0e sequence
alignment/map format and SAMtools,” Bioinformatics,
vol. 25, no. 16, pp. 2078-2079, 2009.
[35] V. Obenchain, M. Lawrence, V. Carey, S. Gogarten,
P. Shannon, and M. Morgan, “VariantAnnotation: a bio-
conductor package for exploration and annotation of genetic
variants,” Bioinformatics, vol. 30, no. 14, pp. 2076–2078, 2014.
[36] X. Chang and K. Wang, “wANNOVAR: annotating genetic
variants for personal genomes via the web,” Journal of Medical
Genetics, vol. 49, no. 7, pp. 433–436, 2012.
[37] M. Lek, K. J. Karczewski, E. V. Minikel et al., “Analysis of
protein-coding genetic variation in 60,706 humans,” Nature,
vol. 536, no. 7616, pp. 285–291, 2016.
[38] N. Rappaport, S. Fishilevich, R. Nudel et al., “Rational con-
federation of genes and diseases: NGS interpretation via
GeneCards, MalaCards and VarElect,” Biomedical Engineer-
ing Online, vol. 16, no. S1, p. 72, 2017.
[39] H. A. Shihab, M. F. Rogers, J. Gough et al., “An integrative
approach to predicting the functional effects of non-coding
and coding sequence variation,” Bioinformatics, vol. 31, no. 10,
pp. 1536–1543, 2015.
[40] R. L. Bowman, Q. Wang, A. Carro, R. G. W. Verhaak, and
M. Squatrito, “GlioVis data portal for visualization and
analysis of brain tumor expression datasets,” Neuro-oncology,
vol. 19, no. 1, pp. 139–141, 2016.
[41] R Core Team, R: A Language and Environment for Statistical
Computing, R Foundation for Statistical Computing, Vienna,
Austria, 2013, http://www.R-project.org/.
[42] M. Giannakis, X. J. Mu, S. A. Shukla et al., “Genomic cor-
relates of immune-cell infiltrates in colorectal carcinoma,”
Cell Reports, vol. 15, no. 4, pp. 857–865, 2016.
[43] G. M. Shankar, A. Taylor-Weiner, N. Lelic et al., “Sporadic
hemangioblastomas are characterized by cryptic VHL inac-
tivation,” Acta Neuropathologica Communications, vol. 2,
no. 1, p. 167, 2014.
[44] S. E. R. Halford, G. Cruickshank, L. Dunn et al., “Results of the
OPARATIC trial: a phase I dose escalation study of olaparib in
combination with temozolomide (TMZ) in patients with
relapsed glioblastoma (GBM),” Journal of Clinical Oncology,
vol. 35, no. 15_suppl, p. 2022, 2017.
[45] A. Liang, B. Zhou, and W. Sun, “Integrated genomic char-
acterization of cancer genes in glioma,” Cancer Cell Inter-
national, vol. 17, no. 1, p. 90, 2017.
[46] C. Xie, H. Sheng, N. Zhang, S. Li, X. Wei, and X. Zheng,
“Association of MSH6 mutation with glioma susceptibility,
drug resistance and progression,” Molecular and Clinical
Oncology, vol. 5, no. 2, pp. 236–240, 2016.
[47] B. E. Johnson, T. Mazor, C. Hong et al., “Mutational analysis
reveals the origin and therapy-driven evolution of recurrent
glioma,” Science, vol. 343, no. 6167, pp. 189–193, 2014.
[48] H. M. Chan and N. B. La0angue, “p300/CBP proteins: HATs
for transcriptional bridges and scaffolds,” Journal of Cell
Science, vol. 114, no. 13, pp. 2363–2373, 2001.
[49] I. Dutto, C. Scalera, and E. Prosperi, “CREBBP and p300
lysine acetyl transferases in the DNA damage response,”
Cellular and Molecular Life Sciences, vol. 75, no. 8,
pp. 1325–1338, 2018.
[50] Z. Yang, X. Chen, J. Piao, Y. Zhao, H. Yin, and Q. Luo,
“Expression of PCAF in brain glioma and its molecular
mechanism,” International Journal of Clinical and Experi-
mental Pathology, vol. 9, no. 3, pp. 3666–3671, 2016.
[51] A. B. Krøiga˚rd, M. J. Larsen, A.-V. Lænkholm et al., “Iden-
tification of metastasis driver genes by massive parallel se-
quencing of successive steps of breast cancer progression,”
PLoS One, vol. 13, no. 1, Article ID e0189887, 2018.
[52] M. K. Mallik, “An attempt to understand glioma stem cell bi-
ology through centrality analysis of a protein interaction net-
work,” Journal of Georetical Biology, vol. 438, pp. 78–91, 2018.
[53] J. A. Chan, H. Zhang, P. S. Roberts et al., “Pathogenesis of
tuberous sclerosis subependymal giant cell astrocytomas:
biallelic inactivation of TSC1 or TSC2 leads to mTOR acti-
vation,” Journal of Neuropathology & Experimental Neurology,
vol. 63, no. 12, pp. 1236–1242, 2004.
[54] D. Burgenske, A. Mladek, and J. Sarkaria, “0e selective ATR
inhibitor VX-970 enhances the therapeutic effects of stan-
dards of care in glioblastoma,” Molecular Cancer Research,
vol. 15, no. 4, 2017.
[55] G. Lombardi, A. Pambuku, L. Bellu et al., “Effectiveness of
antiangiogenic drugs in glioblastoma patients: a systematic
review and metaanalysis of randomized clinical trials,”
Critical Reviews in Oncology/hematology, vol. 111, pp. 94–102,
2017.
[56] N. N. Laack, E. Galanis, S. K. Anderson et al., “Randomized,
placebo-controlled, phase II study of dasatinib with standard
chemoradiotherapy for newly diagnosed glioblastoma
(GBM), NCCTG N0877 (Alliance),” Journal of Clinical On-
cology, vol. 33, no. 15_suppl, 2015.
[57] H. K. Gan, D. A. Reardon, A. B. Lassman et al., “Safety,
pharmacokinetics, and antitumor response of depatuxizumab
Journal of Oncology 13
mafodotin as monotherapy or in combination with temo-
zolomide in patients with glioblastoma,” Neuro-oncology,
vol. 20, no. 6, pp. 838–847, 2017.
[58] A. George, S. Kaye, and S. Banerjee, “Delivering widespread
BRCA testing and PARP inhibition to patients with ovarian
cancer,” Nature Reviews Clinical Oncology, vol. 14, no. 5,
pp. 284–296, 2017.
[59] Y. Lee, J.-K. Lee, S. H. Ahn, J. Lee, and D.-H. Nam, “WNT
signaling in glioblastoma and therapeutic opportunities,”
Laboratory Investigation, vol. 96, no. 2, pp. 137–150, 2016.
[60] J. Zhang, K. Huang, Z. Shi et al., “High -catenin/Tcf-4 activity
confers glioma progression via direct regulation of AKT2 gene
expression,”Neuro-oncology, vol. 13, no. 6, pp. 600–609, 2011.
[61] H. Zhang, Y. Qi, D. Geng et al., “Expression profile and
clinical significance of Wnt signaling in human gliomas,”
Oncology Letters, vol. 15, no. 1, pp. 610–617, 2018.
[62] P. Lu, Y. Wang, X. Liu et al., “Malignant gliomas induce and
exploit astrocytic mesenchymal-like transition by activating
canonical Wnt/β-catenin signaling,” Medical Oncology,
vol. 33, no. 7, p. 66, 2016.
[63] E. K. Onyido, E. Sweeney, and A. S. Nateri, “Wnt-signalling
pathways and microRNAs network in carcinogenesis: ex-
perimental and bioinformatics approaches,” Molecular Can-
cer, vol. 15, no. 1, p. 56, 2016.
[64] D. T. Dang, J. Pevsner, and V. W. Yang, “0e biology of the
mammalian Kru¨ppel-like family of transcription factors,”Ge
International Journal of Biochemistry & Cell Biology, vol. 32,
no. 11-12, pp. 1103–1121, 2000.
[65] S. Wang, X. Shi, S. Wei et al., “Kru¨ppel-like factor 4 (KLF4)
induces mitochondrial fusion and increases spare respiratory
capacity of human glioblastoma cells,” Journal of Biological
Chemistry, vol. 293, no. 17, pp. 6544–6555, 2018.
[66] T. Kantidakis, M. Saponaro, R. Mitter et al., “Mutation of
cancer driver MLL2 results in transcription stress and genome
instability,” Genes & Development, vol. 30, no. 4, pp. 408–420,
2016.
[67] Z. Qian, L. Ren, D. Wu et al., “Overexpression of FOXO3A is
associated with glioblastoma progression and predicts poor
patient prognosis,” International Journal of Cancer, vol. 140,
no. 12, pp. 2792–2804, 2017.
[68] Y.-C. Huang, S.-J. Lin, H.-Y. Shih et al., “Epigenetic regulation
of NOTCH1 and NOTCH3 by KMT2A inhibits glioma
proliferation,” Oncotarget, vol. 8, no. 38, p. 63110, 2017.
[69] H. G.Møller, A. P. Rasmussen, H. H. Andersen, K. B. Johnsen,
M. Henriksen, and M. Duroux, “A systematic review of
microRNA in glioblastoma multiforme: micro-modulators in
the mesenchymal mode of migration and invasion,” Molec-
ular Neurobiology, vol. 47, no. 1, pp. 131–144, 2013.
[70] C. Cilibrasi, G. Riva, G. Romano et al., “Resveratrol impairs
glioma stem cells proliferation andmotility by modulating the
WNT signaling pathway,” PLoS One, vol. 12, no. 1, Article ID
e0169854, 2017.
[71] U. D. Kahlert, M. Cheng, K. Koch et al., “Alterations in
cellular metabolome after pharmacological inhibition of
Notch in glioblastoma cells,” International Journal of Cancer,
vol. 138, no. 5, pp. 1246–1255, 2016.
[72] N. Takebe, P. J. Harris, R. Q. Warren, and S. P. Ivy, “Targeting
cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways,” Nature Reviews Clinical Oncology, vol. 8, no. 2,
pp. 97–106, 2011.
[73] X. Li, W. Deng, S. M. Lobo-Ruppert, and J. M. Ruppert, “Gli1
acts through Snail and E-cadherin to promote nuclear sig-
naling by β-catenin,”Oncogene, vol. 26, no. 31, pp. 4489–4498,
2007.
[74] K. Wang, L. Pan, X. Che, D. Cui, and C. Li, “Gli1 inhibition
induces cell-cycle arrest and enhanced apoptosis in brain
glioma cell lines,” Journal of Neuro-Oncology, vol. 98, no. 3,
pp. 319–327, 2010.
[75] M. H. Shahi, S. Farheen, M. P. M. Mariyath, and
J. S. Castresana, “Potential role of Shh-Gli1-BMI1 signaling
pathway nexus in glioma chemoresistance,” Tumor Biology,
vol. 37, no. 11, pp. 15107–15114, 2016.
[76] J. Kim, I.-H. Lee, H. J. Cho et al., “Spatiotemporal evolution of
the primary glioblastoma genome,” Cancer Cell, vol. 28, no. 3,
pp. 318–328, 2015.
[77] S. Osuka and E. G. Van Meir, “Overcoming therapeutic re-
sistance in glioblastoma: the way forward,” Journal of Clinical
Investigation, vol. 127, no. 2, pp. 415–426, 2017.
[78] J. Wang, E. Cazzato, E. Ladewig et al., “Clonal evolution of
glioblastoma under therapy,” Nature Genetics, vol. 48, no. 7,
pp. 768–776, 2016.
[79] J. M. Findlay, F. Castro-Giner, S. Makino et al., “Differential
clonal evolution in oesophageal cancers in response to neo-
adjuvant chemotherapy,” Nature Communications, vol. 7,
no. 1, p. 11111, 2016.
[80] J. R. Molina, Y. Hayashi, C. Stephens, and M. M. Georgescu,
“Invasive glioblastoma cells acquire stemness and increased
Akt activation,” Neoplasia, vol. 12, no. 6, pp. 453–463, 2010.
[81] W. L. Bi, N. F. Greenwald, S. H. Ramkissoon et al., “Clinical
identification of oncogenic drivers and copy-number alter-
ations in pituitary tumors,” Endocrinology, vol. 158, no. 7,
pp. 2284–2291, 2017.
[82] N. El Hindy, N. Lambertz, H. S. Bachmann et al., “Role of the
GNAS1 T393C polymorphism in patients with glioblastoma
multiforme,” Journal of Clinical Neuroscience, vol. 18, no. 11,
pp. 1495–1499, 2011.
[83] R. Wei, M. Zhao, C. H. Zheng, M. Zhao, and J. Xia, “Con-
cordance between somatic copy number loss and down-
regulated expression: a pan-cancer study of cancer predis-
position genes,” Scientific Reports, vol. 6, no. 1, Article ID
37358, 2016.
[84] K. L. Drucker, C. Gianinni, P. A. Decker, E. P. Diamandis, and
I. A. Scarisbrick, “Prognostic significance of multiple kalli-
kreins in high-grade astrocytoma,” BMCCancer, vol. 15, no. 1,
p. 565, 2015.
14 Journal of Oncology
